Synthesis, Crystal Structure and Biological Activity of 8-((4-((2,3-diaminopyridin-4-yl)oxy)-3-fluorophenyl)-amino)-2-(4-fluorophenyl)-3-methyl-2,7-naphthyridin-1(2H)-one

The new title compound 84(442,3-diaminopyridin-4-yl)-oxy)-3-fluorophenyl)amino)-2-(4-fluorophenyl)-3-methyl-2,7-naphthyridin-1(2H)-one (C26H20F2N6O2, M-r = 486.48) has been prepared and determined by single-crystal X-ray diffraction. The crystal is of monoclinic, space group P2(1)/c with a = 15.365(3), b = 13.144(2), c = 11.863(2) angstrom, beta = 108.882(3)degrees, Z = 4, V= 2267.0(7) angstrom(3), D-c = 1.425 g/cm(3), F(000) = 1008, mu = 0.105 mm(-1), MoKa radiation (lambda= 0.71073 angstrom), R= 0.0480 and wR= 0.1294 for 3197 observed reflections with 1> 2 sigma(4 X-ray diffLaction analysis reveals that the region C (substituents of 8-amino group and 3-methyl group on the 2,7-naphthyridin-1(2H)-one ring) of compound 6 are effectively planar. Intramolecular and intermolecular hydrogen bonds together with pi(...)pi interations are found in the structure. In addition, compound 6 shows potent c-Met and c-Kit kinase inhibition activities.